FDA has expanded the indication for baricitinib (Olumiant) to include adolescents aged 12 years and older with severe alopecia areata, based on results from the Phase 3 BRAVE-AA-PEDS trial.
FDA has expanded the indication for baricitinib (Olumiant) to include adolescents aged 12 years and older with severe alopecia areata, based on results from the Phase 3 BRAVE-AA-PEDS trial.
Oyetewa Boluwatito Asempa, MD, FAAD; Riya Gandhi, MA
Shared decision-making in alopecia areata is often more complex than it appears. Dr Oyetewa Asempa discusses aligning treatment goals, managing expectations, and improving patient-clinician communication.
Shared decision-making in alopecia areata is often more complex than it appears. Dr Oyetewa Asempa discusses aligning treatment goals, managing expectations, and improving patient-clinician communication.
Hair regrowth is only one measure of success in alopecia areata. Dr Zoe Draelos highlights patient-centered outcomes, quality of life, emotional well-being, and long-term disease control.
Hair regrowth is only one measure of success in alopecia areata. Dr Zoe Draelos highlights patient-centered outcomes, quality of life, emotional well-being, and long-term disease control.
Pediatric alopecia areata can have profound emotional and social consequences. Dr Zoe Draelos examines the unique psychological challenges facing children and adolescents with the disease.
Pediatric alopecia areata can have profound emotional and social consequences. Dr Zoe Draelos examines the unique psychological challenges facing children and adolescents with the disease.
